NEWS
April 8, 2009
Cohera Medical Inc. named William M. Cotter to the newly created position of Vice President of Manufacturing
The addition of Cotter, who has over 29 years of Manufacturing and Operations experience in Medical Devices, Diagnostics, Biologics and Life Science industries, comes at a time that Cohera Medical is preparing to enter the clinical stage of development with its lead surgical adhesive product, TissuGlu®.
"Bill spent 10 years as the VP of Operations for Closure Medical Corporation, a medical device company that developed the world's first synthetic topical skin adhesive to be approved by the FDA." said Patrick Daly, president and CEO of Cohera Medical. "We are ramping up our manufacturing activities and Bill brings an extensive amount of industry knowledge and experience. He guided a previous company from early stage R&D through world wide commercialization which led to the company being acquired by Johnson & Johnson. Bill has the proven experience in working with companies in positions similar to ours."
Prior to Closure Medical, Cotter was VP of Operations with Sanofi Diagnostics Pastuer, where he had direct responsibility for all North American manufacturing sites and chaired the World-Wide Manufacturing Committee. Bill is listed as co-inventor on 8 US Patents and has a Bachelor degree from Ohio University
About Cohera Medical
Cohera Medical Inc. is a Pittsburgh-based company that is developing a revolutionary line of wound management products and surgical adhesives. Cohera Medical's products are based on a unique chemical design that is purely synthetic, easy to use, biocompatible and fully resorbable. The company's lead product in development, TissuGlu, is a sprayable bonding agent for plastic surgery procedures. TissuGlu adheres flaps of tissue after surgical procedures, eliminating the spaces where fluid accumulates and reducing wound drainage. Cohera Medical is also developing surgical adhesives targeting mesh fixation and small bone fixation, which will fill similar market needs in both orthopedics and general surgery. For more information, visit http://www.coheramed.com/. TissuGlu and the other Cohera products have not yet been approved for medical use by the Food and Drug Administration (FDA) in the U.S. or by any other country's regulatory authority.